Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.
Hsin-Che LinWen-Juei JengJessica LiuMei-Hung PanMei-Hsuan LeeRichard Batrla-UtermannSheng-Nan LuChuen-Fei ChenHwai-I YangChien-Jen ChenPublished in: Alimentary pharmacology & therapeutics (2024)
Patients with persistently high HBsAg levels during HBeAg-seropositive stage represent a unique population with low risk of HCC development.